How Guerisoli was paid
$3.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Brent J. GuerisoliChief Executive Officer | $444,711 | — | $662,117 | $885,588 | $1,737,874 | $9,186 | $3,739,476 |
| Lynette B. WalbomChief Financial Officer | $338,654 | — | $471,922 | $664,191 | $1,178,055 | $7,606 | $2,660,428 |
| John J. GochnourPresident and Chief Operating Officer | $369,711 | — | $613,016 | $811,789 | $1,586,966 | $10,190 | $3,391,672 |
| Kirk S. CheneyEVP, General Counsel and Corporate Secretary | $285,865 | $500,000 | $134,886 | $516,593 | $365,100 | $283 | $1,802,727 |
| Jason P. SteikChief Clinical Officer | $283,654 | $1,031,274 | — | $516,593 | — | $1,765 | $1,833,286 |
What changed and why
- $3.7MCEO total compensation increased to $3,739,476 in fiscal 2025 from $2,594,080 in fiscal 2024.
- A portion of the annual executive incentive program was paid in fully vested restricted stock awards.
- The CEO-to-median-employee pay ratio was 98 to 1 for 2025.
- Annual and short-term cash bonuses are based on multiple performance metrics consistent with long-term goals.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.